Liam O’Connell, Operations Director at the CK Group attended the ‘What’s the Future for Pharma’ conference on 10th June run by the Yorkshire Chemical Focus (YCF).
This excellent event explored a number of exciting topics from global and European pharmaceutical and economic strategies through to novel areas of research ranging from regenerative medicines and naturally- derived medicines through to the patent cliff.
Speakers came from such notable organisations as Astra Zeneca, HGF, CrystecPharma and the University of Liverpool and it was hosted by YCF (www.ycf.org.uk). They also have a number of exciting events occurring in the near future including a conference on What’s The Future For Waste.
The CK Group are also delighted to announce that we will be sponsoring the YCFs 10th anniversary on the 16th September.
Chemistry World has recently reported on a study into the effectiveness of the allocation of grant money to the scientific community.
The study, conducted by David Currie and Jean-Michel Fortin, biologists at the University of Ottawa, Canada, found that a series of smaller grants to a wider variety of people and institutions is more conducive to effective and meaningful research than large grants to the ‘elite’ in the scientific community. The conclusions of Currie and Fortin indicate that an increased monetary grant does not increase productivity.
Highly cited studies are seemingly unaffected by the level of funding received. The impact generally comes down to the quality of the researchers, regardless of career stage. Some more experienced scientists could have larger grants but less time to perform studies due to other commitments, such as teaching, and so cannot fully use the grant money. It would therefore be better to disseminate the money to a wider variety of researchers so that more diverse research could be performed.
Essentially, the money from grants is better used to improve the scientific community as a whole, rather than for the benefit a few specific areas of research. By funding the elite institutions, it is probably that the vitality and variety of scientific thought will be significantly dulled.
Almac Clinical Services has expanded its business unit by offering the dispensing and bottling of solid dosages, according to the company’s own website.
Added to this, improved containment equipment and processes have been started at Almac’s EU and US headquarters. Dr Robert Dunlop, who is Managing Director of Almac, has said that the company has “experienced an increase in demand for facilities equipped to handle compounds of a higher potency.”
The installation of such facilities has been successful, and Almac has said it is open to and welcoming packaging discussions with companies who are currently developing drugs.
BBC News has reported thatNorbrook Laboratories is set to continue its growth over the next two years, by expanding the workforce to over 2,000.
The Northern Ireland based company, which employs 1,700 people, is adding to the recruitment of 200 new staff already this year. The profitable company has been continually expanding, leading to a recent £150 million investment in the Newry site owned by Norbrook, including new offices, warehouses and production suites.
The new jobs will be across “the full spectrum” of Norbrook’s operations according to James Gibbs, the recruitment manager, with those employed dealing with scientific analysis, production, research, engineering and finance. The Northern Irish pharmaceutical sector has been similarly boosted recently following the creation of jobs at Almac, also based there.
Jason is the Manager of the CK Science Stevenage office, as well as a Senior Recruitment Consultant for the Pharmaceutical, Biotechnology and Food industries. To find out more, please watch his short video below:
The BBC has reported that pharmaceutical companyPfizer’s closure of its Sandwich site, in Kent, could take up to ten years to recover, according to a local councillor.
Over 2,000 jobs are to be lost at the site, and the leader of Kent County Council, Paul Carter, has said that despite there being interest in the site, it will take a long time for a complete recovery. Mr Carter added that it was “a big ask” for a pharmaceutical company to create 2,000 to 3,000 jobs in such a short space of time. He said that should 1,000 jobs be created in 18 months it will have been a good start.
John Westwood, real estate developer at Pfizer, has said that despite there not being “a huge number of organisations or individuals” who could take on the site, there has still been significant interest. A group of politicians has put forward proposals for the centre to be turned into an enterprise zone, which would assist growth.
Business Secretary Vince Cable has opened the Norwich Research Park, set to create 5,000 jobs, reports EDP24.com.
Mr Cable praised the park, calling it “world beating” and “ambitious” as he opened the facility equipped with office space and laboratories. The area the park has been built in is one with a high concentration of food and environmental science businesses, and the project is expected to create around 5,000 jobs over the next fifteen years.
Mr Cable reaffirmed the government’s commitment to the science industry by agreeing to a £26 million investment into the Norwich Research Park, as business plans have been submitted to the government. The park is expected to create the jobs by expanding thanks to the investment.
The investment is expected to create up to 1,000 jobs in one of four UK plants, with Montrose thought to be the front runner due to the recent movement of biomanufacturing of several products from India to the Montrose plant. The Montrose factory also manufactures the products needed to make products that GSK inherited following its acquisition of Steifel in 2009.
Andrew Witty, GSK chief executive, praised the 280 staff at the Montrose factory for turning around what was an ailing site, up for sale at the turn of the Millennium, into a “globally competitive” production plant.